# Neoadjuvant Treatment of Breast Cancer

> **NCT05131893** · — · NOT_YET_RECRUITING · sponsor: **National Institute of Oncology, Hungary** · enrollment: 300 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Goserelin
- **DRUG:** Letrozole 2.5Mg Tab
- **DRUG:** Epirubicin
- **DRUG:** cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** paclitaxel
- **DRUG:** trastuzumab
- **DRUG:** pertuzumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05131893
- **Lead sponsor:** National Institute of Oncology, Hungary
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-03
- **Primary completion:** 2023-03
- **Final completion:** 2031-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2021-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05131893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05131893, "Neoadjuvant Treatment of Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05131893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*